Effects of soy protein and soy phytochemicals on mammary tumor development in female transgenic mice overexpressing human pituitary growth hormone.
The objective of this study was to determine the effect of soy-based diets on mammary tumors in female cancer- prone mice. Transgenic virgin female mice expressing human pituitary growth hormone and their respective phenotypically normal littermates were fed a diet containing either casein (C), low-isoflavone soy protein (LIS), or high-isoflavone soy protein (HIS). Indices of tumor development were measured throughout the study. Both days from birth until death and days on diet until death were increased [by 20% (P = .01) and 19% (P = .02), respectively] in the LIS group when compared with the C group. Both intervals were increased also (by 16% and 17%, respectively; P < .05) in the HIS group when compared with the C group. Days from birth to first tumor were increased by 7% (P < .05), as was days on diet to first tumor by 5% (P < .05), in the LIS group when compared with the C group. First-onset number of tumors was decreased (P = .02) by 41% and 34% in the LIS and C groups, respectively, when compared with the HIS group. Final onset of tumors was decreased (P < .05) by 44% and 9% in the LIS and HIS groups, respectively, when compared with the C group. Total area of final tumors was decreased (P < .05) by 30% in the LIS group when compared with the C group. Taken cumulatively, these data suggest that a diet rich in soy protein may provide protective benefits regarding tumor development in female cancer-prone mice. Furthermore, some bioactive compounds in the HIS diet appeared to confound the soy protein-induced beneficial effects.
Hickey
Jennifer
J
Departments of Animal Science, Food & Nutrition, Southern Illinois University, Carbondale, IL 62901-4317, USA.
Bartke
Andrzej
A
Winters
Todd
T
Henry
Nancy
N
Banz
William
W
D000818:Animals; D004032:Diet; D005260:Female; D015870:Gene Expression; D020022:Genetic Predisposition to Disease; D013006:Growth Hormone / Q000235:genetics*; D007529:Isoflavones / Q000008:administration & dosage*; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D030262:Soybean Proteins / Q000494:pharmacology*; D013025:Glycine max / Q000737:chemistry*
D007529:Isoflavones; D030262:Soybean Proteins; D013006:Growth Hormone